Iconovo initiates feasibility study with Affilogic for development of inhalable Nanofitin®-based biotherapies
Iconovo has entered into a feasibility agreement with Affilogic, a French biotech company, regarding the implementation of a feasibility study of inhalable affinity proteins Nanofitins® in Iconovo’s ICOone. The project aims to develop a new treatment for lung diseases.
– Our new customer project adds additional value to Iconovo, with significant knowledge about the development of biological drugs, a growing market where we see great potential for our unique inhalers, says Johan Wäborg, CEO of Iconovo.
Read the press release here